Phase I trial results suggest that the CD40 ligand inhibitor dapirolizumab pegol is well tolerated and elicits a clinical response in patients with systemic lupus erythematosus.

Patients with inflammatory arthritis who are treated with adalimumab could monitor their blood levels of the drug using a finger prick test in place of full intravenous blood draws, researchers report.

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Results from an Osteoarthritis Initiative study suggest that people whose walking speed slows down over a 1-year period have an increased risk for developing knee osteoarthritis over the following 2 years compared with those who maintain a consistent pace.

Secondary analyses of the RA-BEAM trial suggest that the clinical improvements experienced by rheumatoid arthritis patients treated with baricitinib are accompanied by corresponding gains in patient-reported outcomes.

Results of a Sri Lankan trial suggest that leflunomide and low-dose rituximab have comparable efficacy when used in combination with methotrexate for the treatment of patients with rheumatoid arthritis refractory to first-line non-biologic disease modifying antirheumatic drugs.